Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioXcel Therapeutics (BTAI) Other Operating Expenses (2022 - 2025)

BioXcel Therapeutics has reported Other Operating Expenses over the past 4 years, most recently at $32000.0 for Q4 2025.

  • Quarterly results put Other Operating Expenses at $32000.0 for Q4 2025, down 96.15% from a year ago — trailing twelve months through Dec 2025 was $164000.0 (down 92.35% YoY), and the annual figure for FY2025 was $164000.0, down 92.35%.
  • Other Operating Expenses for Q4 2025 was $32000.0 at BioXcel Therapeutics, up from $11000.0 in the prior quarter.
  • Over the last five years, Other Operating Expenses for BTAI hit a ceiling of $1.2 million in Q3 2024 and a floor of $9000.0 in Q4 2022.
  • Median Other Operating Expenses over the past 4 years was $47000.0 (2024), compared with a mean of $256285.7.
  • Biggest five-year swings in Other Operating Expenses: soared 7833.33% in 2023 and later crashed 99.06% in 2025.
  • BioXcel Therapeutics' Other Operating Expenses stood at $9000.0 in 2022, then soared by 7833.33% to $714000.0 in 2023, then grew by 16.39% to $831000.0 in 2024, then tumbled by 96.15% to $32000.0 in 2025.
  • The last three reported values for Other Operating Expenses were $32000.0 (Q4 2025), $11000.0 (Q3 2025), and $107000.0 (Q2 2025) per Business Quant data.